Breast cancer is the most common malignancy in women in most of countries. According to statistics, the incidence rate in population is 7-10% of various malignant tumors in the body. Its often hereditary disease. And 40-60 years old, postmenopausal women before and after With a higher prevalence. Only about 1-2% of breast patients were male. It is a malignant tumorusually begin to come on Glandular tissue in the breast. it is one of the most common malignant tumor, serious impact on womens health and even life-threatening. Male breast cancer is rare.
A study in Italy last year showed that a new drug triptorelin can reduce the risk of menopause for patients who received chemotherapy. Triptorelin is a new drug for treating patients with pelvic endometriosis after conservative operation.
The researchers made their findings after studying the patients with breast cancer, but They are not post-menopausal. Before chemotherapy, during chemotherapy and a year later, These women were randomly taking triptorelin or placebo. The researchers found that there are over 25% of women entering menopause, but the The triptorelin group is less than 9%. The researchers believe the new drug to treat breast cancer patients with fertility, especially post-menopausal patients.
Triptorelin, a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), is a gonadotropin-releasing hormone agonist (GnRH agonist) used at the acetate or pamoate salts. By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. Triptorelin is marketed under the brand names Decapeptyl (Ipsen) and Diphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold by Watson as Trelstar. During the treatment of prostate cancer it does cause a surge of testosterone (an initial uplevel of testosterone levels), known as a flare effect. In men a reduction of serum testosterone levels into the range normally seen after surgical castration occurs approximately two to four weeks after initiation of therapy. In contrast, gonadotropin-releasing hormone antagonists do not cause a surge, but a sudden reduction of testosterone levels. Systematic IUPAC Name: [d-Trp6]GnRH.